Claritev Stock Earnings Reports

Claritev delivered a strong Q1 2026 driven by record bookings, higher-than-expected revenue and adjusted EBITDA, and continued progress on strategic expansion. Key financials: revenue $244.7M (up 5.8% YoY), adjusted EBITDA $146.9M (60% margin), and $44.1M ACV bookings in Q1 with management reiterating a full-year ACV target of $80M–$100M (20%–50% growth vs. last year). Pipeline increased ~70% YoY, average deal size more than doubled, and the company closed 19 deals >$100k ACV and 9 deals >$1M ACV. Management highlighted product and AI-driven operational improvements (examples: provider contact agent and automated invoice extraction for IDR) that are improving accuracy, efficiency and operating leverage. Strategic wins included a GDIT partnership for the World Trade Center Health Program and a top-5 health system engagement (leveraging the OPCG acquisition), supporting expansion into public sector and provider services. Guidance was modestly raised: full-year revenue guide increased at the low end to $985M–$1.0B, with adjusted EBITDA guidance maintained at $605M–$615M (61%–62% margin). Capital spending and free cash flow expectations remain: total capital $160M–$170M and positive free cash flow; Q1 was a cash use quarter as expected post-refinancing. Management emphasized continued investment in sales, services and AI while pursuing deleveraging over time and targeting multi-year Vision 2030 goals.